Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2025 August
  • Home
  • Archive for August, 2025
Global Trial Podcast
user

Host: Julio Martinez linkedin-img

user

Guest: Ross Youngs linkedin-img


×

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

  • August 29 2025
  • Video - Date: 08/28/2025
  • Length: 29.44

Summary –

Discussed in this Podcast

→ How microbiome mining could cure cancer, Alzheimer’s & more
→ Processing 2 MILLION liters of water daily to extract microbes
→ Accessing drug-like molecules that evolution perfected over 3.4 billion years
→ Why this could be worth TRILLIONS in the next 25 years
→ Transforming agriculture, cosmetics & environmental remediation

lightbulbKEY TAKEAWAY: “Microbes have always been chemical researchers and factories of life. Biosortia’s breakthrough technology now effectively opens the door to ALL microbes.” – Ross Youngs

This technology could literally transform how we discover new medicines and accelerate first-in human trials globally!

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

  • August 15 2025

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Continue Reading

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

  • August 14 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties (August 14, 2025) by Sarah Sutton. Boston, MA — August 14, 2025

Continue Reading

RSS Industry News

  • CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial November 18 2025
  • Vaginal-spray Bacillus spore probiotics as a potential treatment and reducing recurrence of bacterial vaginosis: randomized, double-blind, and controlled pilot study November 18 2025
  • Multi-omic profiling reveals distinct gut microbial and metabolic landscapes in golden snub-nosed monkeys under contrasting conservation strategies November 17 2025
  • Profiling of vaginal microbial communities in Chilean women via self-sampling and nanopore sequencing November 17 2025
  • Microbial regulators of physiological and reproductive health in women of reproductive age: their local, proximal and distal regulatory roles November 17 2025
  • The gut microbiome shapes social behaviour across animal species November 14 2025
  • Characterization of the tumor microbiome of brain metastases and glioblastoma reveals tumor-type-specific and location-specific microbial signatures November 14 2025
  • Assembly, architecture and functional roles of microbial surface layers November 13 2025
  • Augmenting microbial phylogenomic signal with tailored marker gene sets November 12 2025
  • A lysine-restricted diet ameliorates obesity via enrichment of Parabacteroides goldsteinii and 1,4-methylimidazoleacetic acid November 12 2025
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies
  • Novartis goes big for neuroscience with $12B deal for late-stage dystrophy biotech Avidity
  • Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2024. All Rights Reserved